Keywords: Eli Lilly, Acrux, Axiron,, Testosterone replacement, USA, FDA

US FDA approves Axiron, first testosterone replacement from Eli Lilly and Acrux

Article | 25 November 2010

Print This

US drug major Eli Lilly (NYSE: LLY) and Australian partner Acrux (ASX: ACR) have received US Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in